• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Oncolytics Biotech Inc.

    5/8/25 5:18:35 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONCY alert in real time by email
    6-K 1 form6kq1-25date.htm 6-K Document

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K
     
    Report of Foreign Private Issuer
     
    Pursuant to Rule 13a-16 or 15d-16
    of the Securities Exchange Act of 1934
     
    For the month of May 2025
     
    Commission File Number 001-38512
     
    Oncolytics Biotech Inc.
     
    (Translation of registrant's name into English)
     
    Suite 804, 322 11th Avenue SW
    Calgary, Alberta, Canada T2R 0C5
     
    (Address of principal executive offices)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
    Form 20-F   þ
     
    Form 40-F   o
     
    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   o
     
    Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
     
    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   o
     
    Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's “home country”), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.



    EXHIBIT
    NUMBER
    DESCRIPTION
      
    99.1
    Press Release
     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
      
    Oncolytics Biotech Inc.
    (Registrant)
         
         
      By: 
    /s/  Kirk Look
    Date: May 6, 2025Kirk Look
    Chief Financial Officer


    Get the next $ONCY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONCY

    DatePrice TargetRatingAnalyst
    10/6/2022$3.00Buy
    Maxim Group
    More analyst ratings

    $ONCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

      Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Wednesday, May 14, 2025, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter of 2025. Conference Call & Webcast Date: Wednesday, May 14, 2025Time: 4:30 p.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – Interna

      5/6/25 7:00:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

      ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients Ongoing updates support potential of pelareorep combination therapies in one of the deadliest and hardest-to-treat cancers SAN DIEGO and CALGARY, AB, April 24, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will present new data from Cohort 1 of the GOBLET study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 30-June 3, 2025 demonstrating pelareorep's anti-tumor activity in pancreatic ductal adenocarcinoma (PDAC) - the most common form of pancreatic ca

      4/24/25 7:00:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

      SAN DIEGO and CALGARY, AB, April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered into a share purchase agreement (SPA) with Alumni Capital LP (Alumni), an institutional investor. This partnership will provide Oncolytics with a flexible source of funding, enabling the Company to progress pelareorep toward key clinical milestones and minimize dilution to create and sustain shareholder value. The SPA allows Oncolytics to be judicious and plan for the timing and amount of any equity sales, which will be critical as pelareorep's development continues. Under the terms of the agreeme

      4/10/25 6:09:00 PM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Oncolytics Biotech with a new price target

      Maxim Group initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $3.00

      10/6/22 9:22:17 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Oncolytics Biotech with a new price target

      H.C. Wainwright initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $15.00

      2/17/21 2:20:07 PM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCY
    Financials

    Live finance-specific insights

    See more
    • Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

      Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Wednesday, May 14, 2025, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter of 2025. Conference Call & Webcast Date: Wednesday, May 14, 2025Time: 4:30 p.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – Interna

      5/6/25 7:00:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

      Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Feb. 25, 2025 /CNW/ --  Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2024. Conference Call & Webcast Date: Friday, March 7, 2025 Time: 8:30 a.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – International: (437) 900-0527RapidConnect: to join the conference call without operator assistance, plea

      2/25/25 12:43:00 PM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

      Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Feb. 25, 2025 /PRNewswire/ --  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2024. Conference Call & Webcast Date: Friday, March 7, 2025 Time: 8:30 a.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – International: (437) 900-0527RapidConnect: to join the conference call without operator assista

      2/25/25 7:00:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCY
    SEC Filings

    See more
    • SEC Form 6-K filed by Oncolytics Biotech Inc.

      6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

      5/8/25 5:18:35 PM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oncolytics Biotech Inc.

      6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

      4/24/25 11:30:14 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oncolytics Biotech Inc.

      6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

      4/10/25 6:16:03 PM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCY
    Leadership Updates

    Live Leadership Updates

    See more
    • Sernova Corp. Announces Appointment of New Chief Executive Officer

      LONDON, Ontario and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- August 12, 2024. Sernova Corp. ("Sernova" or the "Company") (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, led by an ongoing phase 1/2a clinical trial in type 1 diabetes, is pleased to announce Mr. Jonathan Rigby as the Company's new Chief Executive Officer. James Parsons, on behalf of the Board of Directors of Sernova, stated, "The Board believes that Sernova is now positioned to achieve its strategic milestones under Jonathan's leadership. Jonathan brings a track record of success raising equi

      8/12/24 7:45:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors

      SAN DIEGO and CALGARY, AB, Jan. 9, 2024 /PRNewswire/ --  Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of Patricia S. Andrews to its Board of Directors (the "Board"). "I am pleased to welcome Pat Andrews to our Board of Directors," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. "Pat's extensive board and executive leadership experience navigating first registrational trials in oncology and completing transformational business development agreements with global pharmaceutical companies makes her a natural fit for Oncolytics. As we begin preparations to initiate piv

      1/9/24 7:00:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors

      Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries SAN DIEGO and CALGARY, AB, Sept. 7, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced the appointment of Jonathan Rigby to its Board of Directors. "Jonathan has successfully built, financed, listed, and led several life science companies across a range of therapeutic areas, and I am thrilled to welcome him to our Board," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc. "His extensive executive leadership experience, together with his business development and co

      9/7/22 7:00:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care